Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA295109
Max Phase: Preclinical
Molecular Formula: C36H51F2N3O6
Molecular Weight: 659.81
Molecule Type: Small molecule
Associated Items:
ID: ALA295109
Max Phase: Preclinical
Molecular Formula: C36H51F2N3O6
Molecular Weight: 659.81
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCN(CCC)C(=O)c1cccc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@@H](O)C[C@@H](CC)C(=O)N[C@H]2C[C@@H](OC)C[C@@H](OC)C2)c1
Standard InChI: InChI=1S/C36H51F2N3O6/c1-6-12-41(13-7-2)36(45)26-11-9-10-25(17-26)35(44)40-32(16-23-14-27(37)19-28(38)15-23)33(42)18-24(8-3)34(43)39-29-20-30(46-4)22-31(21-29)47-5/h9-11,14-15,17,19,24,29-33,42H,6-8,12-13,16,18,20-22H2,1-5H3,(H,39,43)(H,40,44)/t24-,29-,30+,31-,32+,33+/m1/s1
Standard InChI Key: PELCHZGPMNNYHX-HMHRWXBJSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 659.81 | Molecular Weight (Monoisotopic): 659.3746 | AlogP: 5.04 | #Rotatable Bonds: 17 |
Polar Surface Area: 117.20 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 9 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 4.33 | CX LogD: 4.33 |
Aromatic Rings: 2 | Heavy Atoms: 47 | QED Weighted: 0.22 | Np Likeness Score: -0.49 |
1. Hom RK, Gailunas AF, Mamo S, Fang LY, Tung JS, Walker DE, Davis D, Thorsett ED, Jewett NE, Moon JB, John V.. (2004) Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human beta-secretase., 47 (1): [PMID:14695829] [10.1021/jm0304008] |
2. Rajamani R, Reynolds CH.. (2004) Modeling the binding affinities of beta-secretase inhibitors: application to subsite specificity., 14 (19): [PMID:15341936] [10.1016/j.bmcl.2004.07.044] |
Source(1):